Ixempra Bar Graphs Land Bristol-Myers Sales Aid In The Slammer

FDA notice of violation letter to the company says its promotion material, which relies heavily on subgroup analyses of secondary endpoints, makes unsubstantiated efficacy claims and broadens the indication for the breast cancer drug.